FDA Approves Autoinjector of Lerodalcibep-Liga With Updated Indication

The FDA approved an autoinjector version of lerodalcibep-liga (Lerochol), a once monthly, self-administered PCSK9 inhibitor for adults with elevated low-density lipoprotein cholesterol (LDL-C). The approval also includes updated indication language reflecting that reducing LDL-C with statins or monoclonal antibody PCSK9 inhibitors lowers the risk for major adverse cardiovascular events in adults at increased risk.¹

The pressure-activated, single-use autoinjector completes dosing in seconds and is expected to reach patients in January 2027.¹

What the New Approval Was For

The new indication states that "cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy." The label update applies across the PCSK9 inhibitor class rather than to lerodalcibep-liga alone.¹

Lerodalcibep was originally approved in December 2025 as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).²

Familial hypercholesterolemia is a genetic condition marked by severely elevated LDL-C that requires lifelong management, and it affects an estimated 1 in 200 individuals worldwide. Cardiovascular disease (CVD) remains the leading cause of death both globally and in the United States, underscoring the demand for additional LDL-C-lowering options that patients can sustain over time.²

Evan Stein, MD, PhD, founder, CEO, and chief scientific officer of LIB Therapeutics, said nearly 40 years of clinical trials have established that lowering LDL-C with statins, and more recently with PCSK9 inhibitors added to statins, further reduces the risk of major cardiovascular events.¹

"These studies have resulted in worldwide consensus and alignment of guidelines on new lower targets and greater additional reductions in LDL-C for the millions of patients who cannot reach guideline-directed LDL-C goals on maximally tolerated statin therapy," Stein said in a news release.¹ "The challenge now, with this newest class of very effective LDL-C lowering agents, is how to make them simple and affordable enough for patients, who must maintain them for what is lifelong treatment."

How the Autoinjector Works

The autoinjector is a pressure-activated, single-use device that delivers a small-volume subcutaneous injection in seconds, according to the company. It carries the same room-temperature storage stability as the existing pre-filled syringe, up to 90 days, and will be priced at $199 per month direct-to-patient, matching the syringe's cash price.¹

LIB Therapeutics said the device is expected to be available in January 2027, with insurance coverage expected to expand gradually through 2027. The pre-filled syringe will remain available as an alternative.¹

Kristen Miller, vice president of brand communications at LIB Therapeutics, said the device was designed with long-term adherence in mind.

"Innovation in PCSK9 inhibition cannot stop at the molecule, because how a medicine for life-long therapy fits into a patient's life is what determines whether they stick with it over the long haul," Miller said in the news release.¹ "The monthly dosing by autoinjector is completed in seconds, does not interfere with any oral medications, require overnight fasting, or limit the timing of food and beverage consumption. These features, along with the extended room temperature storage, mean Lerochol fits into patients' lives and not the other way around."

Clinical Trial Data Behind the Approval

The approval draws on the LIBerate clinical trial program, which enrolled more than 2900 patients across phase 3 trials, including patients with CVD, patients without CVD who are at very high or high risk, and patients with heterozygous or homozygous familial hypercholesterolemia.¹

Over 52 weeks of dosing, lerodalcibep-liga produced sustained LDL-C reductions of at least 60% among patients with CVD and at least 59% among patients with HeFH. In a 72-week open-label extension enrolling more than 2400 patients, the therapy was generally well tolerated, with no serious treatment-related adverse events reported.¹

Dean J. Kereiakes, MD, FACC, MSCAI, chairman of The Christ Hospital Heart and Vascular Institute and professor of medicine at the University of Cincinnati, said PCSK9 inhibitors have been among the most important cardiovascular medicine advances of the past 20 years, but only if patients remain on treatment.

"As much as patients expect highly efficacious and safe therapies, they need therapies that fit into their busy lifestyles, and Lerochol provides a compelling option on both counts," Kereiakes said in the news release.¹ "Lerochol provides substantial LDL-C reduction that achieves the 2026 lipid guidelines in the vast majority of my patients with minimal inconvenience. My patients really appreciate having only once-monthly dosing with Lerochol, and now the availability of the autoinjector further simplifies this important treatment option."

What This Means for Pharmacists

For pharmacists counseling patients on lerodalcibep-liga, the standard adult dose is 300 mg administered by subcutaneous injection once monthly, typically in the abdomen, thigh, or upper arm, with site rotation recommended to reduce skin complications.³

The drug can be stored under refrigeration or at room temperature for up to 3 months, and patients should receive instruction on proper self-injection technique and storage before starting therapy. Ongoing physician monitoring, including periodic blood tests, is recommended throughout treatment, and safety and efficacy have not been established in pediatric patients.³

Common adverse effects pharmacists should discuss with patients include fever, headache, muscle aches, sore throat, stuffy or runny nose, unusual tiredness or weakness, and injection site reactions. Less common effects include swelling in the extremities and changes in weight.³

Because lerodalcibep-liga is intended for lifelong use, pharmacists are well positioned to reinforce the adherence-focused rationale behind the new autoinjector and to help patients weigh the benefits and risks of continued use during counseling, including for patients who are breastfeeding.³

REFERENCES

1. LIB Therapeutics, Inc. U.S. Food and Drug Administration Approves an Autoinjector Version of LEROCHOL (lerodalcibep-liga) and Updated Indication. News release. LIB Therapeutics, Inc. August 17, 2026. Accessed August 17, 2026. https://www.businesswire.com/news/home/20260817106971/en/U.S.-Food-and-Drug-Administration-Approves-an-Autoinjector-Version-of-LEROCHOL-lerodalcibep-liga-and-Updated-Indication

2. National Lipid Association. U.S. Food and Drug Administration Approves LIB Therapeutics' LEROCHOL (lerodalcibep-liga) for Adults With Elevated LDL Cholesterol. National Lipid Association. December 15, 2025. Accessed August 17, 2026. https://www.lipid.org/nla/us-food-and-drug-administration-approves-lib-therapeutics%E2%80%99-lerochol%E2%84%A2-lerodalcibep-liga-adults

3. Mayo Clinic. Lerodalcibep (subcutaneous route). Mayo Clinic. Accessed August 17, 2026. https://www.mayoclinic.org/drugs-supplements/lerodalcibep-liga-subcutaneous-route/description/drg-80008580